Endocrine & hormone · target hub

HSD17B2

17-beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)

HSD17B2 is a Steroidogenic enzyme on the endocrine & hormone axis. Catalyzes the NAD-dependent oxidation of the highly active 17beta-hydroxysteroids, such as estradiol (E2), testosterone (T), and dihydrotestosterone (DHT), to their less active forms and thus regulates the biological potency of these steroids. Oxidizes estradiol to estrone, testo… It is indexed under "Steroidogenesis & steroid-metabolizing enzymes (gonadal/adrenal)" on our pathway page for antibodies, inhibitors, and assay guidance.

Back to pathway overviewSearch: HSD17B2UniProt (P37059)

Research notes

  • Combine with other genes in the same hub block via genetics or pharmacology to test non-redundant roles of HSD17B2.
  • For nuclear receptors pair ligands, co-regulators, and reporter assays; for membrane receptors note GPCR/RTK downstream and desensitization.
  • Verify antibody clone, phospho-site, and stimulation; include KD/KO or inhibitor controls.

On the pathway hub (sections)

Genetic lesions & expression context (quick reference)

Type / exampleDomain / context (brief)
Enzyme activityCatalytic or substrate-channel changes
Steroid outputSteroid profile / metabolite readouts
Rare variantsSporadic variants—require validation

Naming and prevalence vary by cohort and assay—annotate clinically with COSMIC, ClinVar, OncoKB, and datasheets; research context only.

Assay readouts for HSD17B2

  • Enzyme / metabolomics: steroid intermediates at the HSD17B2 step.
  • H295R / primary adrenals: ACTH or cAMP time courses.
  • Localization: mitochondrial STAR transfer or ER P450.
  • Endocrine phenotypes: cortisol/aldosterone/sex-steroid panels.

HSD17B2 experimental notes

Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.

[1] Cell lines commonly used for HSD17B2 studies (examples)

  • Tool lines: H295R, NCI-H295R, BeWo, MA-10, HEK293T—screen by HSD17B2 expression and pathway context (CCLE/DepMap).
  • Combine with neighbors (STAR, CYP11A1, CYP11B1, CYP11B2) via KD/pharmacology to test non-redundancy.
  • Overexpression/rescue in HEK293T supports mechanism and IP workflows.
  • Isogenic/CRISPR models separate pathway dependency from bypass survival.

[2] Cell samples for HSD17B2 Western blot

  • Whole-cell lysates—optimize RIPA/NP-40 per antibody; phosphatase inhibitors for phospho blots.
  • Stimulation: serum starvation ± insulin/EGF or amino-acid withdrawal/refeed as relevant.
  • Controls: siRNA/shRNA, CRISPR KO, or inhibitors to validate band specificity.
  • Loading: BCA normalization; subcellular fractionation when needed.

[3] Tissue samples for HSD17B2 Western blot

  • Matched tumor/adjacent frozen tissues after pathology review.
  • Mouse GEMM or xenografts—mind species antibody cross-reactivity.
  • Primary cells/PDCs when ethically approved.
  • FFPE needs specialized extraction; frozen tissue preferred for phospho work.

[4] Cell samples for HSD17B2 immunoprecipitation

  • Tagged overexpression: HEK293T FLAG/HA-HSD17B2 for complex capture.
  • Endogenous IP: high-expression lines; often ≥1–5×10⁶ cells per IP.
  • Stimulation: ligand or nutrient treatments enrich interactions—pilot time courses.
  • Controls: isotype IgG, empty vector, KD/KO negatives.

Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.

Bypass & related pathways

Models & genetics note

Overexpression vs endogenous HSD17B2 can differ in dosage, splicing, and compartmentation—in organoids/PDX, record passage, matrix, and drug history.

Quick search presets

HSD17B2HSD17B2 antibodyHSD17B2 ligand/agonisthormone/receptor antibody

HSD17B2-related antibodies (keyword-biased)

Adds HSD17B2 keyword bias atop the 内分泌和激素 antibody pool—if sparse, use presets above or global search.

Neighboring targets (same hub)

STARCYP11A1CYP11B1CYP11B2CYP17A1CYP19A1CYP21A2HSD3B1

External databases & resources

FAQ

This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.

Last reviewed: 2026-05-18

Related on this site

See the endocrine & hormone hub for neighboring targets—cross-check PI3K, MAPK, RTK, and metabolism pages as needed.

Endocrine & hormone·PI3K/Akt/mTOR·MAPK/ERK·Receptor tyrosine kinase·Metabolism